FDA approves COVACTA trial for RA drug Actemra in COVID-19 patients

This article was originally published here

The company, which is a subsidiary of Roche, will evaluate the safety and efficacy of Actemra given intravenously plus standard of care in hospitalised adults with severe COVID-19

The post FDA approves COVACTA trial for RA drug Actemra in COVID-19 patients appeared first on Pharmaceutical Business review.

0 replies

Leave a Reply

Want to join the discussion?
Feel free to contribute!

Leave a Reply